Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis



Status:Recruiting
Conditions:Lung Cancer, Lung Cancer, Lung Cancer, Cancer, Cancer, Cancer, Cancer, Cancer, Pneumonia
Therapuetic Areas:Oncology, Pulmonary / Respiratory Diseases
Healthy:No
Age Range:18 - Any
Updated:3/21/2019
Start Date:July 2015
End Date:July 2019
Contact:Andreas Rimner, MD
Phone:212-639-6025

Use our guide to learn which trials are right for you!

Phase II Double-Blind, Randomized, Placebo Controlled Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis

The purpose of this study is to find out what effects, good and/or bad, the drug nintedanib
in combination with steroids, has on the lungs. Furthermore, such treatments' side effects
will be studied together with quality of life. In addition, the investigators would like to
determine whether they can find markers in the blood which predict worsening lung injury.


Inclusion Criteria:

- Histologically/cytologically proven primary thoracic or breast malignancy, lymphoma or
lung metastases (which are not required to be biopsy-proven) treated with definitive
intent at MSK

- Prior treatment with thoracic radiotherapy completed >4 weeks and ≤ 9 months prior to
enrollment

- Radiographic evidence of radiation pneumonitis on a CT scan of the chest with or
without contrast

- Newly diagnosed clinical grade 2 or higher radiation pneumonitis according to CTCAE
version 4.0 criteria

- Age≥18 years

- KPS > 70%

- Reduction of any acute toxicity from radiation treatment to grade 1

- Written informed consent signed prior to entry into the study

Exclusion Criteria:

- Current oral steroid use > 4 weeks prior to registration

- Ongoing treatment with radiotherapy to thorax, cytotoxic or biological therapies for
this malignancy, except the following therapies which are permitted: Pembrolizumab,
Nivolumab, Afatinib and all hormonal therapies.

- Mean esophageal radiation dose >45 Gy

- Diagnosis of diffuse radiation pneumonitis

- Untreated or symptomatic brain metastases or leptomeningeal disease

- Liver metastases

- Other active malignancies requiring oncologic treatment (Note: non-melanoma skin
cancer, superficial bladder cancer etc. are eligible)

- Radiographic evidence of cavitary or necrotic tumor and local invasion of major blood
vessels

- Active chronic Hepatitis C and/or B infection

- Gastrointestinal disorders that would interfere with drug absorption

- AST > 1.5 x ULN, ALT>1.5 x ULN and Bilirubin > 1.5 x ULN

- ≥ Grade 2 proteinuria, creatinine >1.5x ULN or GFR <45 ml/min

- Other investigational therapy received within 8 weeks prior to screening visit

- Pregnant women or women who are breast feeding or of child bearing potential not using
a highly effective method of birth control for at least one month prior to enrollment1

- Sexually active males not committing to birth control during the course of the study
(except if their partner is not of childbearing potential)

- Conditions that may affect the patient's ability to participate in this trial, e.g.
known or suspected active alcohol or drug abuse

- Inherited predisposition to bleeding or thrombosis, INR >2, PT and PTT >1.5x ULN

- History of bleeding disorders or thrombotic events, e.g. hemorrhagic or thrombotic
events within 12 months, clinically significant or tumor-related hemoptysis, active
gastrointestinal bleeding or ulcers or major injuries or surgery

- ANC < 1.5 K/mcL, Platelets < 100 K/mcL, Hemoglobin < 9.0 g/dl

- Concomitant treatment with any of the following drugs: azathioprine, cyclophosphamide,
cyclosporine, pirfenidone, full dose anticoagulation (vitamin K antagonists,
dabigatran, heparin, etc.), fibrinolysis and high dose anti-platelet therapy (ex.
Plavix 150mg)^2 Myocardial infarction or unstable angina within 6 or 1 month of
starting nintedanib treatment, respectively

- Known inherited predisposition to thrombosis

- Patient with a history of a thrombotic event within 12 months of starting nintedanib
treatment

- Known predisposition to bleeding

- Patients with severe hepatic impairment

- History of a gastrointestinal perforation
We found this trial at
10
sites
225 Summit Avenue
Montvale, New Jersey 07645
Phone: 212-639-6025
?
mi
from
Montvale, NJ
Click here to add this to my saved trials
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Phone: 617-632-3591
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials
136 Mountainview Blvd
Basking Ridge, New Jersey 7920
(908) 542-3000
Phone: 212-639-6025
Memorial Sloan-Kettering Cancer Center - Basking Ridge At Memorial Sloan Kettering Basking Ridge, we offer...
?
mi
from
Basking Ridge, NJ
Click here to add this to my saved trials
Commack, New York 11725
Phone: 212-639-6025
?
mi
from
Commack, NY
Click here to add this to my saved trials
500 Westchester Avenue
Harrison, New York 10604
Phone: 212-639-6025
?
mi
from
Harrison, NY
Click here to add this to my saved trials
Houston, Texas 77030
Principal Investigator: Daniel Gomez, MD
Phone: 713-563-8446
?
mi
from
Houston, TX
Click here to add this to my saved trials
Middletown, New Jersey 07748
Phone: 212-639-6025
?
mi
from
Middletown, NJ
Click here to add this to my saved trials
1275 York Ave
New York, New York 10021
(212) 639-2000
Principal Investigator: Andreas Rimner, MD
Phone: 212-639-6025
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
?
mi
from
New York, NY
Click here to add this to my saved trials
1000 N Village Ave
Rockville Centre, New York 11570
(516) 256-3600
Principal Investigator: Andreas Rimner, MD
Phone: 212-639-6025
Memorial Sloan-Kettering at Mercy Medical Center Memorial Sloan Kettering Cancer Center Rockville Centre provides state-of-the-art...
?
mi
from
Rockville Centre, NY
Click here to add this to my saved trials
Uniondale, New York 11553
Phone: 212-639-6025
?
mi
from
Uniondale, NY
Click here to add this to my saved trials